Research Article

In Silico Analysis for Anti-Malarial Activity of 2-Anilino 4-Amino Substituted Quinazolines.

Sumer D. Thakur*¹, Sampatrao B. Suryawanshi², Vijay H. Masand³, Gunwant H. Kurhade⁴

¹Department of Chemistry, RDIK and NKD College, Badnera-Amravati, Amravati- 444701, Maharashtra, India.

²Department of Chemistry, Hutatma Rajguru Mahavidyalaya, Rajgurunagar, Tal. Khed, Pune-410505, Maharashtra, India.

³Department of Chemistry, Vidya Bharati Mahavidyalaya, Amravati-444602, Maharashtra, India.

⁴Department of Chemistry, Vidnyan Mahavidyalaya, Malkapur, Dist. Buldhana-443101, Maharashtra, India

Received 08 December 2018; received in revised form 21 December 2018; accepted 22 December 2018 *Corresponding author E-mail address: sdthakur11@gmail.com

ABSTRACT

In the present work, important structural moieties that govern the anti-malarial activity (3D7) of 2-anilino 4-amino substituted quinazoline derivatives have been identified using consensus pharmacophore modeling. The method encompasses construction of pharmacophore modeling after optimization (MMFF94) followed by field-based alignment of most active three molecules. The study point outs that H-bond donor and acceptor groups as well as aromatic rings are vital for the anti-malarial activity. The outcomes could be advantageous for optimization of 2-anilino 4-amino substituted quinazolines as anti-malarial agents.

KEYWORDS

Pharmacophore modeling, Malaria, 2-anilino 4-amino substituted quinazolines

1. INTRODUCTION

Malaria is neglected disease with high prevalence in developing and undeveloped countries. It is a vector borne disease and *Plasmosdium falciparum* has been identified as the causative agent. The emergence of resistance has worsened the situation; consequently, developing new drugs is very important to eradicate this deadly disease [1-3]. Since, developing a drug is a long and costly process, alternative methods must be employed to have a drug in time.

To accomplish this aim, Computer Aided Drug Designing (CADD) is a method of choice because of advantages like cheaper, eco-benign, easy, fast and outcome focused nature. Hence, it is a better contemporary method for lead optimization. Pharmacophore modeling and QSAR analysis are very common ligand-based drug design (LBDD) thriving methods branches of CADD, especially when the target enzyme is unknown. Consensus pharmacophore modeling is employed widely since it is convenient and recognizes the common pharmacophoric patterns that are linked with the desired activity/property [4-6].

Recently, Gilson *et al* [3] screened2-anilino 4-amino substituted quinazoline derivatives for antimalarial activity. The tested molecules have good variation in activity profile because of wide alterations in substituents. But they did not describe pharmacophoric features/pattern related with anti-malarial activity of 2-anilino 4-amino substituted quinazolines. Henceforth, in the present work, consensus pharmacophore modeling has been done to identify the significant structural moieties that govern the anti-malarial activity of 2-anilino 4-amino substituted quinazoline derivatives.

2. MATERIALS AND METHODS

2.1. Dataset

The dataset consists of fifty-six 2-anilino 4-amino substituted quinazoline derivatives with a variety of substituents like heterocyclic rings, -Br, -OCH₃, -F etc., especially positional isomers. Therefore, the present dataset encompasses wide chemical space. The compounds were tested for anti-malarial activity (3D7). The activity values described as EC_{50} (μ M) range from 26 to 7700. The dataset has been tabulated in table 1.

Table 1. Different substituted 2-anilino 4-amino substituted quinazolines along with reported EC_{50} used in the present work.

S. No	R ¹	\mathbf{R}^2	R ³	\mathbf{R}^4	Pf Parasite EC ₅₀ (μM)

$\begin{array}{c ccccccccccccccccccccccccccccccccccc$						
1		\mathbb{R}^{1} \mathbb{R}^{3} \mathbb{R}^{2} \mathbb{R}^{2} \mathbb{R}^{2} \mathbb{R}^{3}	R ⁴			
2 h H H OCH ₃ 7700 3 h H H OCH ₃ 1800 4 h H H OCH ₃ 329 5 h H H OCH ₃ 155 7 NHCH ₃ H H F 136 8 h H H F 136 9 h H H CH ₃ 109 10 h H H CH ₃ 109 10 h H H CH 113 12 h H H CI 113 14 h h H H H 14 h h H <t< th=""><th>1</th><th>H</th><th>Н</th><th>Н</th><th>OCH₃</th><th>124</th></t<>	1	H	Н	Н	OCH ₃	124
3	2		Н	Н	OCH ₃	7700
4	3	N N	Н	Н	OCH ₃	1800
5 $\stackrel{NH}{MH}$ H -OCH2O- 7.8 6 NHCH3 H H OCH3 155 7 NHCH3 H H F 136 8 N H H F 136 8 N H H F 136 9 $\stackrel{O}{G}$ H H F 418 9 $\stackrel{O}{G}$ H H CH3 109 10 $\stackrel{O}{G}$ H H CH3 109 10 $\stackrel{O}{G}$ H H Br 125 11 $\stackrel{O}{G}$ H H Cl 113 12 $\stackrel{O}{G}$ H H F 112 14 $\stackrel{O}{G}$ H F H 134 15 $\stackrel{O}{MH}$ H F H 317 16 $\stackrel{O}{O}$ F H H CO ₂ CH3 574 18 $\stackrel{O}{G}$ H H CH(CH3)OH 702	4	OH	Н	Н	OCH ₃	329
6 NHCH3 H H H OCH3 155 7 NHCH3 H H F 136 8 N H H F 136 9 \sim H H F 418 9 \sim H H CH3 109 10 \sim H H Br 125 11 \sim H H Br 125 11 \circ H H Cl 113 12 \circ H H F 112 14 \circ H Cl H 134 15 \circ H F H 144 16 \circ F H H 317 17 \circ H H H Clustrational states 18 \sim H H H Clustrational states	5	NH NH	Н	-OCH ₂ C)-	7.8
7 NHCH3 H H F 136 8 $\[mathbb{k]\]$ H H F 418 9 $\[mathbb{k]\]$ H H F 418 9 $\[mathbb{k]\]$ H H CH3 109 10 $\[mathbb{k]\]$ H H CH3 109 11 $\[mathbb{k]\]$ H H CH3 109 11 $\[mathbb{k]\]$ H H C1 113 12 $\[mathbb{k]\]$ H H C1 H 134 15 $\[mathbb{k]\]$ H F H 144 16 $\[mathbb{k]\]$ H H C0_2CH3 574 18 $\[mathbb{k]\]$ H H CH(CH3)OH 702	6	NHCH ₃	Н	Н	OCH ₃	155
8 N H H F 418 9 \rightarrow H H CH ₃ 109 10 \rightarrow H H Br 125 11 \rightarrow H H Cl 113 12 \rightarrow H H Cl 113 12 \rightarrow H H F 112 14 \rightarrow H Cl H 134 15 \rightarrow H F H 317 16 \rightarrow F H H co_2cH_3 574 18 \rightarrow H H $cH(cH_3)OH$ 702	7	NHCH ₃	Н	Н	F	136
9 \rightarrow H H CH ₃ 109 10 \rightarrow H H Br 125 11 \rightarrow H H Cl 113 12 \rightarrow H H Cl 113 12 \rightarrow H H F 112 14 \rightarrow H Cl H 134 15 \rightarrow H F H 144 16 \rightarrow F H H 317 17 \rightarrow H H Cucuta 574 18 \rightarrow H H Cu(cuta)0H 702	8	 N_	Н	Н	F	418
10 \downarrow H H Br 125 11 \downarrow H H Cl 113 12 \downarrow H H F 112 14 \downarrow H H F 112 14 \downarrow H Cl H 134 15 \downarrow H F H 144 16 \downarrow F H H 317 17 \downarrow H H CO ₂ CH ₃ 574 574 18 \downarrow H H CH(CH ₃)OH 702	9	O NH	Н	Н	CH ₃	109
NH H H Cl 113 12 \overrightarrow{NH} H H F 112 14 $\overrightarrow{O_{NH}}$ H Cl H F 112 14 $\overrightarrow{O_{NH}}$ H Cl H 134 15 $\overrightarrow{O_{NH}}$ H F H 144 16 $\overrightarrow{O_{NH}}$ F H H 317 17 $\overrightarrow{O_{NH}}$ H H CO ₂ CH ₃ 574 18 $\overrightarrow{O_{N}}$ H H CH(CH ₃)OH 702	10		Н	Н	Br	125
12 $rightarrow$ H H F 112 14 $rightarrow$ H Cl H 134 15 $rightarrow$ H F H 144 16 $rightarrow$ F H H 317 17 $rightarrow$ H H CO ₂ CH ₃ 574 18 $rightarrow$ H H CH(CH ₃)OH 702	11		Н	Н	Cl	113
14 \checkmark HClH13415 \checkmark HFH14416 \checkmark FH31717 \checkmark HHCO ₂ CH ₃ 57418 \checkmark HH702	12	NH	Н	Н	F	112
$15 \qquad H \qquad F \qquad H \qquad 144$ $16 \qquad H \qquad F \qquad H \qquad 317$ $17 \qquad H \qquad H \qquad CO_2CH_3 \qquad 574$ $18 \qquad H \qquad H \qquad CH(CH_3)OH \qquad 702$	14	o	Н	Cl	Н	134
$16 \qquad \overbrace{NH} F \qquad H \qquad H \qquad 317$ $17 \qquad \overbrace{O} H \qquad H \qquad CO_2CH_3 \qquad 574$ $18 \qquad \overbrace{O} H \qquad H \qquad CH(CH_3)OH \qquad 702$	15	NH NH	Н	F	Н	144
NH H H CO₂CH₃ 574 17 Image: Second sec	16	o	F	Н	Н	317
18	17	NH O	Н	Н	CO ₂ CH ₃	574
NH	18	NH o NH	Н	Н	CH(CH ₃)OH	702

Curr. Pharm	. Res.	2019,	9(2),	2759-2765
-------------	--------	-------	-------	-----------

19	0	Н	Н	C(O)NH ₂	691		
	NH						
20	0	Н	Н	C(O)NH ₂	569		
21	NH ⁻	Н	Н	NHAc	274		
	NH						
22	o	Н	-OCH ₂ O-		8.6		
23	NH O	Н	OCH	Н	230		
	NH			••			
24	o	OCH ₃	Н	Н	526		
25	NH	OCH ₃	Н		1100		
26	NH	OCH ₃	OCH ₃	Н	1300		
		2					
		R ³					
27	H	Н	OCH ₃		264		
28		Н	OCH ₂ CH ₃		159		
29		Н	F		77		
30		Н	CF ₃		105		
31		Cl	Br		137		
32		Cl	F		56		
33		F	Cl		121		
34		(N)	CF ₃		102		
		2					
(A) N R^3							
35	→ → →	\int	Н	F	57		

Curr	Pharm	Res	2019	9(2)	2759-2765
Curr.	i nurm.	nes.	201 <i>)</i> ,	<i>∕(2)</i> ,	2137-2103

36		Bn	Н	F	41
37	N	Bn	Н	F	539
38		Bn	Н	F	636
39	N	Bn	Н	F	57
40	S	Bn	Н	F	866
41	N K	Bn	Н	F	1200
42	N N N	Bn	Н	F	7600
43	N	N N	Cl	F	110
44	N		F	Cl	128
45	N	N	Cl	F	134
46	N N	N N	F	Cl	283
47	Ar	N,	Н	F	104
48	Ar	N	Н	F	42
49	Ar	Y NO	Н	F	118
50	Ar	N N	Н	F	77
51	Ar		Н	F	64
52	Ar	V V	Н	Cl	51
53	Ar		Cl	F	26
		\checkmark			

Curr. Pharm. Res. 2019, 9(2), 2759-2765

54	Ar	N N	F	Cl	27
55	Ar	N N	Cl	F	35
56	Ar	N N	F	Cl	28

2.2. Structure drawing, optimization and alignment

ChemSketch 12 freeware was used to draw all the structures, followed by structure optimization using MMFF94 force field available in TINKER. In the next step, Open3dAlign software was used to align all the optimized structures. The aligned structures were imported in PyMOI 2.2forconsensus pharmacophore modeling using LIQUID plugin fusing the default settings [4-6].

3. RESULTS AND DISCUSSION

The consensus pharmacophore modeling identified that the anti-malarial activity is associated with seven pharamcophoric features. The central pharmacophoric feature contains the occurrence of three aromatic rings in a triangular arrangement. These three aromatic rings contribute toward hydrophobic nature of the molecule. The pharmacophore pattern also comprises of two H-bond donor groups positioned inside the trio of lipophilic aromatic rings. The pharmacophoric pattern also includes two lipophilic centers close to one of the rings. The following figure depicts this consensus pharmacophoric pattern along with their respective distances (shown using green color).



Figure 1. Consensus pharmacophoric pattern using the active molecule 26 as a representative only (Yellow: Hydrophobic, Green: H-bond donor groups)

Curr. Pharm. Res. 2019, 9(2), 2759-2765

4. CONCLUSION

Consequently, in future optimizations, the three-cornered arrangement of hydrophobic aromatic rings, two H-bond donor groups and two additional lipophilic center close to one of the rings must be retained for retention of anti-malarial activity.

5. REFERENCES

- Shibi, I. G., Aswathy, L., Jisha, R. S., Masand, V. H., Divyachandran, A., & Gajbhiye, J. M. (2015). Molecular docking and QSAR analyses for understanding the antimalarial activity of some 7-substituted-4-aminoquinoline derivatives. *Eur J Pharm Sci*, 77, 9-23.
- [2] Singh, K., Okombo, J., Brunschwig, C., Ndubi, F., Barnard, L., Wilkinson, C., Chibale, K. (2017). Antimalarial Pyrido [1, 2-a] benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model. *Journal of Medicinal Chemistry*, 60(4), 1432-1448.
- [3] Gilson, P. R., Tan, C., Jarman, K. E., Lowes, K. N., Curtis, J. M., Nguyen, W., . . . Sleebs, B. E. (2017). Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity. *Journal of Medicinal Chemistry*, 60(3), 1171-1188.
- [4] Masand, V. H., & Rastija, V. (2017). PyDescriptor : A new PyMOL plugin for calculating thousands of easily understandable molecular descriptors. *Chemometrics and Intelligent Laboratory Systems, 169*, 12-18.
- [5] Masand, V. H., El-Sayed, N. N. E., Mahajan, D. T., & Rastija, V. (2017). QSAR analysis for 6-arylpyrazine-2-carboxamides as Trypanosoma brucei inhibitors. SAR and QSAR in Environmental Research, 28(2), 165-177.
- [6] Masand, V. H., El-Sayed, N. N. E., Mahajan, D. T., Mercader, A. G., Alafeefy, A. M., & Shibi, I. G. (2017). QSAR modeling for anti-human African trypanosomiasis activity of substituted 2-Phenylimidazopyridines. *Journal of Molecular Structure*, *1130*, 711-718.